Celgene's Solid Quarter Enhanced By Strong Interim Data For Revlimid
This article was originally published in The Pink Sheet Daily
Executive Summary
A pivotal trial to expand labeling to first-line multiple myeloma therapy was stopped after the first interim data readout due to strong PFS data.
You may also be interested in...
Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share
NICE posts positive recommendation for Vidaza payment in England, Wales.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.